Johnson & Johnson strengthens diabetes line with Animas acquisition
This article was originally published in Clinica
Executive Summary
Animas saw its shares rocket 32% to close at $24.03 on December 16 after Johnson & Johnson agreed to acquire the West Chester, Pennsylvania-based insulin delivery company in a cash-and-stock merger transaction valued at around $518m.